NCT07318051Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study
Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 9600 (estimated)
- First submitted
- 19 Dec 2025
- Start date
- 21 Jul 2025
- Primary completion date
- Jan 2035
- Lead sponsor
- Natera, Inc.
- Diseases
- Prostate cancer, Head and neck cancer, Bladder cancer, Melanoma, Lung cancer, Pancreatic cancer, Colorectal cancer, Liver and biliary tract cancer, Ovarian cancer
- NCT number
- NCT07318051
What you commit to
- Study type: Observational
- Planned participants: 9600
- From 21 Jul 2025 to the primary completion date, Jan 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers.
Other illness
- At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection.
- History of bone marrow or organ transplant.
- Serious medical conditions that may adversely affect ability to participate in the study.
Other
- Pregnant or breastfeeding.
- Has initiated postoperative systemic treatment.
Who the study is looking for
- 18 years of age or older.
- Any patient that has an untreated primary solid malignancy within the following cohorts:
- Breast cancer
- Lung cancer
- Muscle invasive bladder cancer
- Rectal cancer
- Pancreatic cancer
- Ovarian cancer
- Gastroesophageal cancer
- Prostate cancer
- Melanoma
- Hepatic/liver cancer
- Uterine/endometrial cancer
- Head and neck Cancer
- The participant has a suspected primary malignancy of pancreatic, endometrial, bladder, or ovarian cancer based on imaging.
- Eastern Cooperative Oncology Group performance status ≤ 2.
- Able to tolerate venipuncture for research blood draw(s).
- Consent to provide residual tumor tissue for research.
- Willing and able to comply with the study requirements.
- Signed informed consent(s) must be obtained prior to participation in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Natera, Inc. Coordinator of this site? Confirm its status | Austin | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.